Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 2
2005 10
2006 14
2007 16
2008 17
2009 31
2010 26
2011 52
2012 43
2013 50
2014 47
2015 50
2016 63
2017 60
2018 60
2019 79
2020 85
2021 106
2022 98
2023 126
2024 114
2025 125
2026 113

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,266 results

Results by year

Filters applied: . Clear all
Page 1
Decreased METTL3 in atrial myocytes promotes atrial fibrillation.
Shi J, Zhu XY, Yu RH, Liu WX, Yang J, Tang L, Kong CY, Luo HQ, Chen F, Xie WS, Fu JL, Wang JJ, Zhou Q, Zhou Q, Wang DJ. Shi J, et al. Europace. 2025 Feb 5;27(2):euaf021. doi: 10.1093/europace/euaf021. Europace. 2025. PMID: 39991872 Free PMC article.
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
Chen Z, Yang F, Jiang Z, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Li W, Lu D, Hu M, Maxwell Wang Z, Li B, Xia M, Lu S. Chen Z, et al. Among authors: shi j. Lancet. 2025 Nov 1;406(10515):2078-2088. doi: 10.1016/S0140-6736(25)01848-3. Epub 2025 Oct 19. Lancet. 2025. PMID: 41125109 Clinical Trial.
The authors reply.
Xu S, Kong X, Shi J, Huang J, Lu B. Xu S, et al. Among authors: shi j. Crit Care Med. 2025 Dec 1;53(12):e2774-e2775. doi: 10.1097/CCM.0000000000006903. Epub 2025 Dec 2. Crit Care Med. 2025. PMID: 41342845 No abstract available.
Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
Guo S, Liu X, Zhang J, Huang Z, Ye P, Shi J, Stalin A, Wu C, Lu S, Zhang F, Gao Y, Jin Z, Tao X, Huang J, Zhai Y, Shi R, Guo F, Zhou W, Wu J. Guo S, et al. Among authors: shi j. Comput Biol Med. 2023 Jul;161:107066. doi: 10.1016/j.compbiomed.2023.107066. Epub 2023 May 27. Comput Biol Med. 2023. PMID: 37263064
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.
Lu S, Liu B, Luo Y, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Chen Z, Li W, Lu D, Hu M, Wang ZM, Li B, Xia MY. Lu S, et al. Among authors: shi j. Lancet. 2026 Jun 27;407(10548):2620-2629. doi: 10.1016/S0140-6736(26)00966-9. Epub 2026 May 31. Lancet. 2026. PMID: 42218899 Clinical Trial.
1,266 results